Genmab A/S ADS (GMAB) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Genmab A/S ADS, updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$57.29
+28.25% today
Market cap
$27.9B
Overall quality
—
Kronos AI 30-day
−33.0%
0 of 8 simulated paths end higher
Genmab A/S ADS (GMAB) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $27.9B. It trades at $57.29, up 28.25% today. 11 analysts' average target of $94.89 implies +65.6% from today's price. Kronos AI's 30-day forecast is −33.0% (0 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $94.89 |
| Low – high | $42.00 – $357.22 |
| Analysts | 11 |
| Upside to average | +65.6% |
Kronos AI 30-day forecast
| Expected close | $29.94 (−33.0%) |
| Likely range | −37.4% … −31.8% |
| As of | 2026-10-27 |
0 of 8 simulated paths end higher.
Quality scores
Not scored: the financial data for this listing is incomplete.
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.